Skip to content
- Efficacy of PARP inhibition combined with EZH2 inhibition depends on BRCA mutation status and microenvironment in breast cancer.
- Chen MK.
- FEBS J. 2021 Feb 11. doi: 10.1111/febs.15730. Epub ahead of print.
- Molecular analyses of triple-negative breast cancer in the young and elderly.
- Aine M, Boyaci C, Hartman J, Häkkinen J, Mitra S, Campos AB, Nimeus E, Ehinger A, Vallon-Christersson J, Borg Å, Staaf J.
- Breast Cancer Res. 2021 Feb 10;23(1):20. doi: 10.1186/s13058-021-01392-0.
- How to start niraparib in real-world Asian ovarian cancer patients?
- Hong SH.
- J Gynecol Oncol. 2021 Feb 8:e36. doi: 10.3802/jgo.2021.32.e36. Epub ahead of print.